000 | 01936 a2200505 4500 | ||
---|---|---|---|
005 | 20250514035943.0 | ||
264 | 0 | _c20020913 | |
008 | 200209s 0 0 eng d | ||
022 | _a0959-8049 | ||
024 | 7 |
_a10.1016/s0959-8049(02)00081-3 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPolee, M B | |
245 | 0 | 0 |
_aPhase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. _h[electronic resource] |
260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cJul 2002 |
||
300 |
_a1495-500 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
650 | 0 | 4 |
_aDiarrhea _xchemically induced |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 |
_aEsophageal Neoplasms _xdrug therapy |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHematologic Diseases _xchemically induced |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInfusions, Intravenous |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMaximum Tolerated Dose |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNervous System Diseases _xchemically induced |
650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
650 | 0 | 4 | _aSurvival Analysis |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aVerweij, J | |
700 | 1 | _aSiersema, P D | |
700 | 1 | _aTilanus, H W | |
700 | 1 | _aSplinter, T A W | |
700 | 1 | _aStoter, G | |
700 | 1 | _aVan der Gaast, A | |
773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 38 _gno. 11 _gp. 1495-500 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0959-8049(02)00081-3 _zAvailable from publisher's website |
999 |
_c12001825 _d12001825 |